Drugs / Glimepiride
Glimepiride
also known as
Amaryl · HOE 490 · Sulfonylurea · Amaryl - glimepiride · glim · glimepiride (Amaryl) · Glimepirida · Glimepiride component of avandaryl · +6 more
Regulatory milestones approvals, filings & regulatory actions · 5 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | EU (EMA) | Avaglim | — | 2006-06-27 | europa.eu ↗ |
| Label expansions (3) | US (FDA) | AMARYL | — | 1999-02-24 – 2005-11-28 | fda.gov ↗ |
| Approved | US (FDA) | AMARYL | — | 1995-11-30 | fda.gov ↗ |
Trials 71 · started per year
today
US approved 1995
EU approved 2006
1
3
4
3
2
3
2
2
4
7
4
4
7
4
1
4
2
7
1
1
1
1
1
2
1995199619971998199920002001200220032004200520062007200820092010201120122013201420152016201720182019202020212022202320242025202620272028
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 117 trials | ||||||
| Phase 1 | NCT06644404 | Oct → Dec 2024 overdue | — | Daewoong Pharmaceutical Co. LTD. | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT03009513 | Jan → May 2017 | diabetes mellitus | Handok Inc. | Completed | No outcome recorded |
| Phase 1 | NCT02954822 | Nov 2016 → Jan 2017 | type 2 diabetes mellitus | Dong-A ST Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT02395237 | May 2015 | — | Pharmaceutical Research Unit, Jordan | Withdrawn | No outcome recorded |
| Phase 1 | NCT01768455 | Feb → Apr 2013 | — | LG Life Sciences | Completed | No outcome recorded |
| Phase 1 | NCT01614769 | Jul 2012 → Jan 2013 | type 2 diabetes mellitus | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 1 | NCT01496443 | Jan → May 2012 | — | Takeda | Completed | No outcome recorded |
| Phase 1 | NCT01437813 | Jan 2011 | — | Laboratorios Silanes S.A. de C.V. | Completed | No outcome recorded |
| Phase 1 | NCT01437800 | Jan 2011 | — | Laboratorios Silanes S.A. de C.V. | Completed | No outcome recorded |
| Phase 1 | NCT01133431 | May → Jun 2010 | — | Chong Kun Dang Pharmaceutical | Completed | No outcome recorded |
| Phase 1 | NCT01302158 | Dec 2009 → Apr 2010 | — | Astellas Pharma Inc | Completed | No outcome recorded |
| Phase 1 | NCT02172261 | Apr → Jun 2009 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT00934323 | Oct → Nov 2008 | — | Handok Inc. | Completed | No outcome recorded |
| Phase 1 | NCT00934817 | Mar → May 2007 | — | Handok Inc. | Completed | No outcome recorded |
| Phase 1 | NCT00650533 | Nov → Dec 2004 | — | Mylan Pharmaceuticals Inc | Completed | No outcome recorded |
| Phase 1 | NCT00648362 | Nov 2004 | — | Mylan Pharmaceuticals Inc | Completed | No outcome recorded |
| Phase 1 | NCT00835172 | Mar 2003 | — | Teva Pharmaceuticals USA | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT01425580 | Jan 2012 → Aug 2016 | congestive heart failure, type 2 diabetes mellitus | Thomas Nystrom | Completed | No outcome recorded |
| Phase 320 trials | ||||||
| Phase 3 | NCT07288749 | Jan 2026 → Dec 2030 expected | heart failure, type 2 diabetes mellitus | Tongji Hospital | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT04841096 | Mar 2023 → Mar 2024 | type 2 diabetes mellitus | Laboratorios Silanes S.A. de C.V. | Completed | No outcome recorded |
| Phase 3 | NCT03060980 | Mar 2017 → Jan 2018 | type 2 diabetes mellitus | Intarcia Therapeutics | Terminated | No outcome recorded |
| Phase 3 | NCT02484209 | Feb → Oct 2016 | diabetes mellitus | Diabetes Frail Ltd | Withdrawn | No outcome recorded |
| Phase 3 | NCT02419612 | Aug 2015 → Aug 2017 | type 2 diabetes mellitus | AstraZeneca | Completed | No outcome recorded |
| Phase 3 | NCT01863667 | Jul 2013 → Apr 2014 | type 2 diabetes mellitus | Merck Sharp & Dohme LLC | Terminated | No outcome recorded |
| Phase 3 | NCT01699932 | Sep 2012 → Apr 2014 | type 2 diabetes mellitus | Sanofi | Completed | No outcome recorded |
| Phase 3 | NCT01459809 | Feb 2012 → Jan 2014 | type 2 diabetes mellitus | Sanofi | Completed | No outcome recorded |
| Phase 3 | NCT01477853 | Oct 2011 → Dec 2012 | type 2 diabetes mellitus | Merck Sharp & Dohme LLC | Terminated | No outcome recorded |
| Phase 3 | NCT01296412 | Mar 2011 → Feb 2012 | type 2 diabetes mellitus | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 3 | NCT01243424 | Nov 2010 → Aug 2018 | type 2 diabetes mellitus | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 3 | NCT00614120 | Jan 2008 → Feb 2009 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 3 | NCT00770952 | Dec 2006 → Dec 2008 | type 2 diabetes mellitus | Takeda | Completed | No outcome recorded |
| Phase 3 | NCT00437554 | Aug 2006 → Jul 2007 | type 2 diabetes mellitus | Handok Inc. | Completed | No outcome recorded |
| Phase 3 | NCT00151697 | May 2005 → ? | type 2 diabetes mellitus | Rijnstate Hospital | Completed | No outcome recorded |
| Phase 3 | NCT00353691 | Oct 2002 → Nov 2004 | type 2 diabetes mellitus | Sanofi | Completed | No outcome recorded |
| Phase 3 | NCT00783744 | Dec 2001 → Aug 2003 | type 2 diabetes mellitus | Sanofi | Completed | No outcome recorded |
| Phase 3 | NCT00044447 | May 2001 → Sep 2002 | type 2 diabetes mellitus | Sanofi | Completed | No outcome recorded |
| Phase 3 | NCT00379769 | Apr 2001 → Dec 2008 | type 2 diabetes mellitus | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT00032487 | Dec 2000 → May 2008 | type 2 diabetes mellitus | VA Office of Research and Development | Completed | No outcome recorded |
| Phase 428 trials | ||||||
| Phase 4 | NCT05386186 | Jan 2022 → Oct 2023 | type 2 diabetes mellitus | Peking University People's Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT04287387 | Mar 2020 → Mar 2021 | type 2 diabetes mellitus | Peking Union Medical College Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT03693560 | Oct 2018 → Sep 2019 | coronary artery disorder, type 2 diabetes mellitus | Damanhour University | Completed | No outcome recorded |
| Phase 4 | NCT03804411 | Aug 2017 → Mar 2020 | type 2 diabetes mellitus | Federal State Budgetary Institution, V. A. Almazov Federal North-West Medical Research Centre, of the Ministry of Health | Unknown | No outcome recorded |
| Phase 4 | NCT03118713 | Apr 2017 → Dec 2018 | type 2 diabetes mellitus | Astellas Pharma Inc | Terminated | No outcome recorded |
| Phase 4 | NCT04239586 | Apr 2017 → Apr 2022 | maturity-onset diabetes of the young type 1, maturity-onset diabetes of the young type 3, type 1 diabetes mellitus | Haukeland University Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT04237493 | Feb → Jul 2017 | type 2 diabetes mellitus | University of Jordan | Completed | No outcome recorded |
| Phase 4 | NCT02973477 | Jan 2017 → Aug 2019 | cardiovascular disorder, type 2 diabetes mellitus | University of Michigan | Completed | No outcome recorded |
| Phase 4 | NCT02373865 | Sep 2015 → Jan 2017 | type 2 diabetes mellitus | GWT-TUD GmbH | Terminated | No outcome recorded |
| Phase 4 | NCT01890629 | May 2013 → Aug 2014 | type 2 diabetes mellitus | LG Life Sciences | Completed | No outcome recorded |
| Phase 4 | NCT01812122 | Mar 2013 → Aug 2015 | type 2 diabetes mellitus | Seoul National University Hospital | Completed | No outcome recorded |
| Phase 4 | NCT01660386 | Jul → Dec 2012 | type 2 diabetes mellitus | Shanghai Jiao Tong University School of Medicine | Unknown | No outcome recorded |
| Phase 4 | NCT01341717 | Feb 2012 → May 2014 | type 2 diabetes mellitus | Jothydev's Diabetes and Research Centre | Completed | No outcome recorded |
| Phase 4 | NCT01204580 | Dec 2010 → Mar 2012 | type 2 diabetes mellitus | Sanofi | Completed | No outcome recorded |
| Phase 4 | NCT01144728 | May → Dec 2010 | type 2 diabetes mellitus | Sanofi | Completed | No outcome recorded |
| Phase 4 | NCT00957060 | Jul 2009 → Oct 2010 | type 2 diabetes mellitus | Sanofi | Completed | No outcome recorded |
| Phase 4 | NCT00913367 | May 2009 → Nov 2010 | type 2 diabetes mellitus | Handok Inc. | Completed | No outcome recorded |
| Phase 4 | NCT00908921 | Apr 2009 → Sep 2010 | type 2 diabetes mellitus | Sanofi | Completed | No outcome recorded |
| Phase 4 | NCT00941161 | Feb 2009 → May 2010 | type 2 diabetes mellitus | Laboratorios Silanes S.A. de C.V. | Completed | No outcome recorded |
| Phase 4 | NCT00700856 | Sep 2008 → Dec 2018 | cardiovascular disorder, type 2 diabetes mellitus | Italian Society of Diabetology | Unknown | No outcome recorded |
| Phase 4 | NCT00708578 | May 2008 → Dec 2009 | type 2 diabetes mellitus | Sanofi | Completed | No outcome recorded |
| Phase 4 | NCT01429818 | Jul 2007 → Jan 2008 | type 2 diabetes mellitus | Laboratorios Silanes S.A. de C.V. | Completed | No outcome recorded |
| Phase 4 | NCT00318656 | Nov 2005 → Oct 2007 | type 2 diabetes mellitus | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 4 | NCT02142309 | Oct 2005 → Oct 2015 | type 2 diabetes mellitus | University of Campania Luigi Vanvitelli | Unknown | No outcome recorded |
| Phase 4 | NCT00619697 | Dec 2003 → Mar 2005 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 4 | NCT00642915 | Jun 2003 → Jul 2004 | diabetes mellitus | Sanofi | Completed | No outcome recorded |
| Phase 4 | NCT00633425 | Oct 2002 → Oct 2003 | type 2 diabetes mellitus | Sanofi | Completed | No outcome recorded |
| Phase 4 | NCT00133718 | Jan 2002 → Apr 2006 | type 2 diabetes mellitus | Asker & Baerum Hospital | Completed | No outcome recorded |
| Phase not applicable5 trials | ||||||
| — | NCT07589387 | May 2026 → Apr 2029 expected | diabetes mellitus | Washington University School of Medicine | Not yet recruiting | No outcome recorded |
| — | NCT02443922 | Jun → Dec 2015 | type 2 diabetes mellitus | Foundation for the National Institutes of Health | Unknown | No outcome recorded |
| — | NCT02026310 | Jan 2014 → Nov 2015 | type 2 diabetes mellitus | Qifu Li | Completed | No outcome recorded |
| — | NCT00978263 | Feb 2009 → Dec 2011 | diabetes mellitus | Chongqing Medical University | Completed | No outcome recorded |
| — | NCT00608179 | Aug 2002 → Sep 2004 | type 2 diabetes mellitus | Vanderbilt University | Completed | No outcome recorded |
Also used as a comparator or background therapy in 153 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 17 trials | ||||||
| Phase 1 | NCT02956044 Comparator | Nov 2016 → Mar 2017 | type 2 diabetes mellitus | Theracos | Completed | No outcome recorded |
| Phase 1 | NCT01703286 Comparator | Oct 2012 → Jan 2014 | type 2 diabetes mellitus | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT01725672 Comparator | Sep 2012 → Aug 2013 | type 2 diabetes mellitus | GlaxoSmithKline | Terminated | No outcome recorded |
| Phase 1 | NCT00842556 Comparator | Mar → May 2009 | type 2 diabetes mellitus | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT00562250 Comparator | May → Aug 2008 | type 2 diabetes mellitus | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT01511692 Comparator | Nov 2005 → Sep 2007 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT00834340 Comparator | Feb → Mar 2003 | — | Teva Pharmaceuticals USA | Completed | No outcome recorded |
| Phase 29 trials | ||||||
| Phase 2 | NCT02111096 Background | Apr 2014 → Sep 2015 | type 2 diabetes mellitus | Eli Lilly and Company | Terminated | No outcome recorded |
| Phase 2 | NCT01699737 Comparator | Sep 2012 → May 2013 | type 2 diabetes mellitus | Akros Pharma Inc. | Completed | No outcome recorded |
| Phase 2 | NCT01517373 Comparator | Feb 2012 → Jan 2013 | type 2 diabetes mellitus | Pfizer | Completed | No outcome recorded |
| Phase 2 | NCT01408095 Comparator | Sep 2011 → Sep 2012 | type 2 diabetes mellitus | Eli Lilly and Company | Withdrawn | No outcome recorded |
| Phase 2 | NCT01007097 Comparator | Dec 2009 → Sep 2010 | type 2 diabetes mellitus | Takeda | Completed | No outcome recorded |
| Phase 2 | NCT00792935 Comparator | Jan 2009 → Feb 2010 | type 2 diabetes mellitus | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 2 | NCT00309608 Comparator | Apr 2006 → Aug 2007 | type 2 diabetes mellitus | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 2 | NCT01511172 Comparator | Aug → Dec 2002 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 2 | NCT01509755 Comparator | Oct 2000 → Oct 2001 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 2/33 trials | ||||||
| Phase 2/3 | NCT01610934 Comparator | Aug 2012 → Aug 2013 | maturity-onset diabetes of the young | University Hospital, Gentofte, Copenhagen | Completed | No outcome recorded |
| Phase 2/3 | NCT01318135 Comparator | Jan 2009 → Jan 2010 | type 2 diabetes mellitus | Takeda | Completed | No outcome recorded |
| Phase 2/3 | NCT01318083 Comparator | Aug 2008 → Apr 2009 | type 2 diabetes mellitus | Takeda | Completed | No outcome recorded |
| Phase 367 trials | ||||||
| Phase 3 | NCT03332771 Comparator | Dec 2017 → Aug 2019 | type 2 diabetes mellitus | Lexicon Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT03066830 Comparator | Feb 2017 → Apr 2019 | type 2 diabetes mellitus | Lexicon Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT02946632 Comparator | Dec 2016 → Dec 2019 | type 2 diabetes mellitus | Korea University Anam Hospital | Unknown | No outcome recorded |
| Phase 3 | NCT02769481 Comparator | Aug 2016 → Jun 2019 | type 2 diabetes mellitus | Theracos | Completed | No outcome recorded |
| Phase 3 | NCT02630706 Background | Dec 2015 → Dec 2017 | type 2 diabetes mellitus | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 3 | NCT02226003 Background | Sep 2014 → Feb 2016 | type 2 diabetes mellitus | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 3 | NCT02089126 Background | Jun 2014 → Sep 2016 | type 2 diabetes mellitus | LG Life Sciences | Unknown | No outcome recorded |
| Phase 3 | NCT02099110 Background | Apr 2014 → May 2016 | type 2 diabetes mellitus | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 3 | NCT02036515 Background | Mar 2014 → Jun 2016 | type 2 diabetes mellitus | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 3 | NCT01999218 Comparator | Dec 2013 → Apr 2017 | type 2 diabetes mellitus | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 3 | NCT01958671 Background | Oct 2013 → Jul 2016 | type 2 diabetes mellitus | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 3 | NCT01841697 Background | Jun 2013 → Nov 2014 | type 2 diabetes mellitus | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 3 | NCT01794143 Comparator | May 2013 → Apr 2021 | type 2 diabetes mellitus | GRADE Study Group | Completed | No outcome recorded |
| Phase 3 | NCT01829477 Background | Apr 2013 → Feb 2014 | type 2 diabetes mellitus | Takeda | Terminated | No outcome recorded |
| Phase 3 | NCT01455922 Comparator | Feb 2013 → Jul 2014 | type 2 diabetes mellitus | Intarcia Therapeutics | Withdrawn | No outcome recorded |
| Phase 3 | NCT01455883 Comparator | Feb 2013 → Jul 2014 | type 2 diabetes mellitus | Intarcia Therapeutics | Withdrawn | No outcome recorded |
| Phase 3 | NCT01755156 Comparator | Jan 2013 → Mar 2016 | type 2 diabetes mellitus | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 3 | NCT01769378 Background | Jan 2013 → Dec 2014 | type 2 diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 3 | NCT01717313 Background | Dec 2012 → Jun 2015 | type 2 diabetes mellitus | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 3 | NCT01704261 Background | Oct 2012 → Dec 2014 | type 2 diabetes mellitus | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 3 | NCT01678820 Background | Oct 2012 → Nov 2013 | type 2 diabetes mellitus | Merck Sharp & Dohme LLC | Terminated | No outcome recorded |
| Phase 3 | NCT01682759 Comparator | Sep 2012 → Jan 2015 | type 2 diabetes mellitus | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 3 | NCT01590771 Background | Jul 2012 → Jun 2014 | type 2 diabetes mellitus | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 3 | NCT01644500 Comparator | Jul 2012 → Aug 2014 | type 2 diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 3 | NCT01585792 Comparator | May → Dec 2012 | — | Takeda | Completed | No outcome recorded |
| Phase 3 | NCT01584232 Background | Apr 2012 → Jul 2013 | type 2 diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 3 | NCT01494987 Background | Jan 2012 → Aug 2013 | type 2 diabetes mellitus | Gilead Sciences | Completed | No outcome recorded |
| Phase 3 | NCT01481116 Comparator | Jan 2012 → Mar 2014 | type 2 diabetes mellitus | Takeda | Terminated | No outcome recorded |
| Phase 3 | NCT01495013 Comparator | Dec 2011 → Apr 2013 | type 2 diabetes mellitus | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT01457911 Comparator | Oct 2011 → Feb 2013 | type 2 diabetes mellitus | Sanofi | Completed | No outcome recorded |
| Phase 3 | NCT01177384 Background | Jan 2011 → Mar 2013 | type 2 diabetes mellitus | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 3 | NCT01262586 Comparator | Nov 2010 → Mar 2011 | type 2 diabetes mellitus | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT01242215 Background | Sep 2010 → Apr 2012 | type 2 diabetes mellitus | Astellas Pharma Inc | Completed | No outcome recorded |
| Phase 3 | NCT01189890 Comparator | Aug 2010 → Oct 2012 | type 2 diabetes mellitus | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 3 | NCT01167881 Comparator | Aug 2010 → Aug 2013 | type 2 diabetes mellitus | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 3 | NCT01340768 Comparator | Jun 2010 → Sep 2011 | type 2 diabetes mellitus | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 3 | NCT01076075 Background | Jun 2010 → Jul 2011 | type 2 diabetes mellitus | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 3 | NCT01453049 Comparator | Apr → Oct 2010 | type 2 diabetes mellitus | GlaxoSmithKline | Terminated | No outcome recorded |
| Phase 3 | NCT01087502 Comparator | Mar 2010 → May 2012 | type 2 diabetes mellitus | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 3 | NCT01075282 Background | Feb 2010 → May 2012 | type 2 diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 3 | NCT00968812 Comparator | Sep 2009 → Dec 2011 | type 2 diabetes mellitus | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 3 | NCT00974090 Comparator | Sep 2009 → Mar 2011 | type 2 diabetes mellitus | Tanabe Pharma Corporation | Completed | No outcome recorded |
| Phase 3 | NCT02314637 Background | Aug 2009 → Jul 2011 | type 2 diabetes mellitus | Tanabe Pharma Corporation | Completed | No outcome recorded |
| Phase 3 | NCT00924573 Background | May 2009 → Mar 2010 | type 2 diabetes mellitus | Sanofi | Completed | No outcome recorded |
| Phase 3 | NCT00838903 Comparator | Feb 2009 → Jan 2012 | type 2 diabetes mellitus | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT00839527 Background | Feb 2009 → Jan 2012 | type 2 diabetes mellitus | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT00740051 Comparator | Aug 2008 → Aug 2010 | type 2 diabetes mellitus | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 3 | NCT00701090 Comparator | May 2008 → Oct 2009 | type 2 diabetes mellitus | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 3 | NCT00680745 Background | Apr 2008 → Nov 2009 | type 2 diabetes mellitus | AstraZeneca | Completed | No outcome recorded |
| Phase 3 | NCT00622284 Comparator | Feb 2008 → Dec 2010 | type 2 diabetes mellitus | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 3 | NCT00620282 Comparator | Feb 2008 → May 2010 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 3 | NCT00469586 Comparator | Apr 2007 → Apr 2008 | type 2 diabetes mellitus | Novo Nordisk A/S | Terminated | No outcome recorded |
| Phase 3 | NCT00770653 Comparator | Apr 2007 → May 2009 | hyperlipidemia, type 2 diabetes mellitus | Takeda | Completed | No outcome recorded |
| Phase 3 | NCT00449605 Comparator | Mar 2007 → Nov 2008 | type 2 diabetes mellitus | Sanofi | Terminated | No outcome recorded |
| Phase 3 | NCT00427154 Comparator | Jan 2007 → Mar 2008 | type 2 diabetes mellitus | Novo Nordisk A/S | Terminated | No outcome recorded |
| Phase 3 | NCT00343980 Background | Oct 2006 → Mar 2008 | type 2 diabetes mellitus | Novo Nordisk A/S | Terminated | No outcome recorded |
| Phase 3 | NCT00359762 Comparator | Sep 2006 → Mar 2011 | type 2 diabetes mellitus | AstraZeneca | Completed | No outcome recorded |
| Phase 3 | NCT00318422 Background | May 2006 → May 2007 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 3 | NCT00331851 Background | May 2006 → Apr 2007 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 3 | NCT00318461 Comparator | May 2006 → May 2007 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 3 | NCT00294723 Comparator | Feb 2006 → Nov 2008 | type 2 diabetes mellitus | Novo Nordisk A/S | Terminated | No outcome recorded |
| Phase 3 | NCT00131664 Comparator | Sep 2005 → Jan 2008 | type 2 diabetes mellitus | Canadian Heart Research Centre | Completed | No outcome recorded |
| Phase 3 | NCT00106340 Comparator | Mar 2005 → May 2008 | type 2 diabetes mellitus | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT00099944 Background | May 2004 → Oct 2005 | type 2 diabetes mellitus | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT00225264 Comparator | Oct 2003 → May 2006 | type 2 diabetes mellitus | Takeda | Completed | No outcome recorded |
| Phase 3 | NCT00225277 Comparator | Jul 2003 → Oct 2007 | type 2 diabetes mellitus | Takeda | Completed | No outcome recorded |
| Phase 3 | NCT00000620 Background | Sep 1999 → Jun 2009 | atherosclerosis, coronary artery disorder, hyperlipoproteinemia, hypertensive disorder +1 | National Heart, Lung, and Blood Institute (NHLBI) | Completed | No outcome recorded |
| Phase 451 trials | ||||||
| Phase 4 | NCT07365358 Comparator | Mar 2026 → Aug 2027 expected | type 2 diabetes mellitus | Chong Kun Dang Pharmaceutical | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT06759922 Comparator | Jan → Mar 2025 | type 2 diabetes mellitus | Bahria University | Completed | No outcome recorded |
| Phase 4 | NCT06449235 Comparator | Sep 2024 → Apr 2025 overdue | type 2 diabetes mellitus | Bangladesh Institute of Research and Rehabilitation in Diabetes, Endocrine and Metabolic Disorders | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT05975528 Comparator | Jun 2023 → Dec 2025 | type 2 diabetes mellitus | Yonsei University | Unknown | No outcome recorded |
| Phase 4 | NCT04528212 Background | Nov 2020 → Nov 2021 | type 2 diabetes mellitus | Rehab Werida | Completed | No outcome recorded |
| Phase 4 | NCT05663736 Comparator | Jan 2020 → Oct 2023 | — | Seoul National University Bundang Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT02823808 Comparator | Jul 2017 → Jul 2021 | diabetes mellitus | Kyunghee University Medical Center | Unknown | No outcome recorded |
| Phase 4 | NCT02985242 Comparator | Jun 2017 → Aug 2018 | type 2 diabetes mellitus | Hannover Medical School | Terminated | No outcome recorded |
| Phase 4 | NCT02919059 Comparator | Dec 2016 → Dec 2018 | type 2 diabetes mellitus | IInstituto Gallego de Medicina Vascular | Unknown | No outcome recorded |
| Phase 4 | NCT02694263 Comparator | Jul 2016 → Sep 2018 | type 2 diabetes mellitus | University of Leicester | Completed | No outcome recorded |
| Phase 4 | NCT02728453 Comparator | Apr 2016 → Sep 2017 | type 2 diabetes mellitus | Hannover Medical School | Terminated | No outcome recorded |
| Phase 4 | NCT04183868 Comparator | Apr 2016 → Oct 2021 | type 2 diabetes mellitus | University of Catanzaro | Completed | No outcome recorded |
| Phase 4 | NCT03983551 Comparator | Mar 2016 → Feb 2018 | proteinuria, type 2 diabetes mellitus | Changhua Christian Hospital | Completed | No outcome recorded |
| Phase 4 | NCT02564926 Comparator | Jan 2016 → Jan 2018 | type 2 diabetes mellitus | AstraZeneca | Completed | No outcome recorded |
| Phase 4 | NCT04470310 Comparator | Dec 2015 → May 2019 | type 2 diabetes mellitus | Seoul National University Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT02649465 Comparator | Nov 2015 → Dec 2020 | NAFLD1 | Kanazawa University | Completed | No outcome recorded |
| Phase 4 | NCT02471404 Comparator | Sep 2015 → Mar 2017 | type 2 diabetes mellitus | AstraZeneca | Completed | No outcome recorded |
| Phase 4 | NCT02528019 Comparator | Aug 2015 → Aug 2017 | — | Kurume University | Unknown | No outcome recorded |
| Phase 4 | NCT02462369 Comparator | Jun 2015 → Apr 2017 | proteinuria | The Second Hospital of Nanjing Medical University | Unknown | No outcome recorded |
| Phase 4 | NCT02372955 Comparator | Feb 2015 → Feb 2016 | type 2 diabetes mellitus | Gulf Regional Research & Educational Services, LLC | Unknown | No outcome recorded |
| Phase 4 | NCT02312063 Comparator | Feb 2015 → May 2016 | type 2 diabetes mellitus | Kansai Electric Power Hospital | Completed | No outcome recorded |
| Phase 4 | NCT02426294 Comparator | Feb → Dec 2015 | type 2 diabetes mellitus | Pusan National University Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT02301806 Comparator | Jan 2015 → Jun 2017 | type 2 diabetes mellitus | Dokkyo Medical University | Unknown | No outcome recorded |
| Phase 4 | NCT02280486 Comparator | Jan 2015 → Oct 2016 | type 2 diabetes mellitus | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | Completed | No outcome recorded |
| Phase 4 | NCT02106104 Comparator | Mar 2014 → Apr 2016 | type 2 diabetes mellitus | Amsterdam UMC, location VUmc | Completed | No outcome recorded |
| Phase 4 | NCT02072096 Comparator | Feb 2014 → Oct 2015 | type 2 diabetes mellitus | Eli Lilly and Company | Terminated | No outcome recorded |
| Phase 4 | NCT02007278 Comparator | Jan 2014 → Feb 2016 | hypoglycemia, type 2 diabetes mellitus | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 4 | NCT01972724 Background | Dec 2013 → Oct 2016 | type 2 diabetes mellitus | Takeda | Completed | No outcome recorded |
| Phase 4 | NCT01910441 Comparator | Jul 2013 → Sep 2014 | type 2 diabetes mellitus | Novartis Pharmaceuticals | Terminated | No outcome recorded |
| Phase 4 | NCT01709305 Comparator | Nov 2012 → Apr 2015 | type 2 diabetes mellitus | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 4 | NCT01593137 Comparator | May 2012 → Dec 2013 | type 2 diabetes mellitus | Fundación Fernández-Cruz | Withdrawn | No outcome recorded |
| Phase 4 | NCT01547104 Comparator | Apr → Oct 2012 | type 2 diabetes mellitus | Marcus Borchert | Unknown | No outcome recorded |
| Phase 4 | NCT01565096 Comparator | Nov 2011 → Nov 2012 | type 2 diabetes mellitus | ikfe-CRO GmbH | Unknown | No outcome recorded |
| Phase 4 | NCT01509001 Comparator | Jan 2011 → Jan 2012 | type 2 diabetes mellitus | University of Sao Paulo | Completed | No outcome recorded |
| Phase 4 | NCT01444248 Comparator | Aug 2010 → Dec 2011 | type 2 diabetes mellitus | Handok Inc. | Completed | No outcome recorded |
| Phase 4 | NCT01087567 Comparator | Jul 2010 → Jan 2014 | type 2 diabetes mellitus | Ohio University | Completed | No outcome recorded |
| Phase 4 | NCT01131182 Comparator | Jun → Nov 2010 | type 2 diabetes mellitus | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 4 | NCT01404676 Comparator | Jun 2010 → May 2012 | type 2 diabetes mellitus | Samsung Medical Center | Completed | No outcome recorded |
| Phase 4 | NCT00993187 Comparator | May 2010 → Oct 2013 | type 2 diabetes mellitus | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 4 | NCT01123980 Background | May 2010 → Jun 2011 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 4 | NCT00939939 Comparator | Mar 2010 → May 2011 | type 2 diabetes mellitus | Ludwig-Maximilians - University of Munich | Terminated | No outcome recorded |
| Phase 4 | NCT01099137 Comparator | Jan 2010 → Dec 2012 | type 2 diabetes mellitus | Seoul National University Bundang Hospital | Completed | No outcome recorded |
| Phase 4 | NCT01006603 Comparator | Oct 2009 → Jun 2012 | type 2 diabetes mellitus | AstraZeneca | Completed | No outcome recorded |
| Phase 4 | NCT00949442 Background | Jul 2009 → Jul 2012 | type 2 diabetes mellitus | Sanofi | Completed | No outcome recorded |
| Phase 4 | NCT00858013 Comparator | Apr 2009 → Jun 2014 | type 2 diabetes mellitus | Ajou University School of Medicine | Completed | No outcome recorded |
| Phase 4 | NCT00699322 Comparator | Jun 2008 → Jun 2010 | type 2 diabetes mellitus | The Catholic University of Korea | Unknown | No outcome recorded |
| Phase 4 | NCT00562172 Comparator | Sep 2007 → Oct 2010 | type 2 diabetes mellitus | Sanofi | Completed | No outcome recorded |
| Phase 4 | NCT00469092 Background | May 2007 → Apr 2008 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 4 | NCT00474838 Comparator | Apr 2007 → Aug 2012 | type 2 diabetes mellitus | Kyunghee University Medical Center | Completed | No outcome recorded |
| Phase 4 | NCT00360698 Background | Jul 2006 → Aug 2008 | type 2 diabetes mellitus | Sanofi | Completed | No outcome recorded |
| Phase 4 | NCT00576784 Comparator | Apr 2005 → Apr 2007 | type 2 diabetes mellitus | IKFE Institute for Clinical Research and Development | Completed | No outcome recorded |
| Phase not applicable16 trials | ||||||
| — | NCT06068686 Comparator | Oct 2022 → Nov 2024 | type 2 diabetes mellitus | Damanhour University | Completed | No outcome recorded |
| — | NCT03907423 Comparator | Apr 2019 → Jan 2021 | type 2 diabetes mellitus | Rehab Werida | Completed | No outcome recorded |
| — | NCT03917940 Comparator | Jan 2019 → May 2020 | — | Damanhour University | Completed | No outcome recorded |
| — | NCT03180281 Comparator | Jul 2017 → Jan 2020 | type 2 diabetes mellitus | First Affiliated Hospital Xi'an Jiaotong University | Unknown | No outcome recorded |
| — | NCT03081676 Comparator | Mar 2017 → Jun 2018 | maturity-onset diabetes of the young type 3 | University Hospital, Gentofte, Copenhagen | Completed | No outcome recorded |
| — | NCT02964572 Comparator | Nov 2016 → Jul 2017 | type 2 diabetes mellitus | Yonsei University | Completed | No outcome recorded |
| — | NCT02609815 Comparator | Nov 2015 → Mar 2021 | type 2 diabetes mellitus | Seoul National University Bundang Hospital | Completed | No outcome recorded |
| — | NCT01951339 Comparator | Oct 2013 → Jun 2018 | cardiovascular disorder, type 2 diabetes mellitus | University of Colorado, Denver | Completed | No outcome recorded |
| — | NCT01819402 Comparator | Mar 2012 → Apr 2013 | — | Kurume University | Unknown | No outcome recorded |
| — | NCT01561976 Comparator | Jan → Feb 2012 | type 2 diabetes mellitus | GlaxoSmithKline | Completed | No outcome recorded |
| — | NCT01183104 Comparator | Aug 2010 → Jan 2015 | type 2 diabetes mellitus | Japan Association for Diabetes Education and Care | Completed | No outcome recorded |
| — | NCT00775684 Comparator | Oct 2008 → Nov 2012 | prediabetes syndrome, type 2 diabetes mellitus | University of Pennsylvania | Completed | No outcome recorded |
| — | NCT00747383 Comparator | Sep 2008 → Sep 2010 | type 2 diabetes mellitus | The Royal Bournemouth Hospital | Completed | No outcome recorded |
| — | NCT00679237 Comparator | Sep 2007 → Dec 2019 | coronary artery disorder | Sorlandet Hospital HF | Completed | No outcome recorded |
| — | NCT00722631 Comparator | May 2007 → Apr 2009 | atherosclerosis, glucose intolerance, type 2 diabetes mellitus | Kurume University | Completed | No outcome recorded |
| — | NCT00506194 Comparator | Oct 2005 → Aug 2007 | type 2 diabetes mellitus | Taipei Veterans General Hospital, Taiwan | Completed | No outcome recorded |
Press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2005-10-06 | Teva Branded Pharmaceutical Products R&D, Inc. | Teva Announces Approval of Glimepiride Tablets tevapharm.com ↗ |
| 2005-06-28 | Teva Branded Pharmaceutical Products R&D, Inc. | Teva Announces Tentative Approval Of Glimepiride Tablets tevapharm.com ↗ |
Evidence & citations 18 cited values
Every value below carries the sentence it was read from. 229 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | glimepiride | “The purpose of this study is to evaluate the safety and efficacy of MP-513 (Teneligliptin) as monotherapy or in combination with Sulfonylurea (glimepiride) in Japanese patients...” NCT02314637 ↗217“The SU was gradually increased to the maximum permitted dose (glibenclamide 15 mg per day or miconizied equivalent of 10.5 mg per day; gliclazide 240 mg per day; glimepiride 4...” NCT00379769 ↗ “Glimepiride, oral tablets, initiated at 1 mg daily and titrated up to the maximum approved dose (8 mg daily based on the local country label) or maximum tolerated dose” NCT01999218 ↗ “Subsequently, patients are assigned to receive either the DPP-4 inhibitor Vildagliptin 50 mg twice daily or the sulfonylurea Glimepiride 2 mg twice daily.” NCT03983551 ↗ “The combination of glimepiride(amaryl) and short-acting insulin (novorapid) is thought to attain glycemic control with a smaller increase in body weight.” NCT00151697 ↗ “glimepiride (starting dose 1 mg/day and up-titrated, based upon patient's self-monitoring of blood glucose results, to a maximum dose of up to 6 mg/day)” PMID 21199268 ↗ Feb 2011 “This Arm will include patients receiving Sulphonylureas (Gliclazide/ Glipizide/ Glimepiride/ Tolbutamide) according to the physician's choice.” NCT06449235 ↗ “Sulfonylurea (glibenclamide, glimepiride, or gliclazide) administered orally daily over the Ramadan period as per physician's prescription” NCT01131182 ↗ “Routine Care patients receive oral medications based upon the 2009 ADA treatment recommendations: Metformin, Glimepiride, Pioglitazone.” NCT01087567 ↗ “If the patients fail to achieve the target, gliclazide-MR (Diamicron, Servier), or glimepiride (Amaryl, Sanofi-Aventis) would be added.” NCT00978263 ↗ “OAMs included sulfonylureas (SU; glibenclamide, gliclazide, or glimepiride) and/or biguanides (BG; metformin or buformin).” NCT01584232 ↗ “a sulfonylurea (5-15 mg glibenclamide, 2-6 mg glimepiride, or 30-120 mg gliclazide, in accordance with local practice)” PMID 28917544 ↗ Sep 2017 “Diabetic patients treated with Rosuvastatin 10mg/day plus Glimepiride 1-8mg/day and Metformin 500-2550 mg/day oral” NCT03907423 ↗ “The combination of glimepiride and metformin is used for glycemic control in patients with diabetes mellitus.” PMID 22036245 ↗ Oct 2011 “glimepiride dose will be increased by 50% to uncontrolled diabetic patients with glimepiride and metformin” NCT01099137 ↗ “same glimepiride/metformin hydrochloride (HCl) 2 mg/1000 mg fixed dose combination (FDC) tablets” NCT02395237 ↗ “polypharmacy for glucose control (metformin, repaglinide/glimepiride, pioglitazone or insulin)” NCT00133718 ↗ “Pre-study sulfonylurea therapy consisted of either glibenclamide, glimepiride or gliclazide.” NCT01340768 ↗ “Glimepiride oral tablet(s) - total daily dose of 1 to 6 mg once a day as rescue therapy” NCT01841697 ↗ “subgroup 7A - addition of glimepiride, subgroup 8A - addition of gliclazide” NCT03804411 ↗ “Group who takes Glimepiride 2mg+Metformin 500mg, once daily.” NCT02823808 ↗ “glimepiride 2 mg & metformin HCl 500 mg” NCT00934817 ↗ “Gliclazide-MR, Metformin, Glimepiride” NCT00506194 ↗ “MP-513","Amaryl","glimepiride” NCT00974090 ↗ “Glimepiride 2mg, once daily” NCT06644404 ↗ “glimepiride (Amaryl)” NCT00000620 ↗ “Glimepiride 1-2mg qd” NCT03180281 ↗ “Glimepiride” NCT02919059 ↗ “Glimepiride” NCT02946632 ↗ “Glimepiride” NCT01242215 ↗ |
| Known as | Amaryl | “commercially available formulations of metformin extended release (XR) (GLUCOPHAGE ™ Sustained Release \[SR\]) and glimepiride immediate release (IR) (AMARYL ™).” NCT01725672 ↗9“If the patients fail to achieve the target, gliclazide-MR (Diamicron, Servier), or glimepiride (Amaryl, Sanofi-Aventis) would be added.” NCT00978263 ↗ “AvandiaTM and AmarylTM combine two antidiabetic agents, rosiglitazone maleate and glimepiride.” NCT00131664 ↗ “Glimepiride (Amaryl) 4 mg oral dose during protocol, given once during each protocol.” NCT00608179 ↗ “Dosage of 1mg, 2mg and 4mg of AMARYL (Glimepiride)” NCT00908921 ↗ “Amaryl® Tablets 1 mg” NCT00650533 ↗ “AMARYL (Glimepiride)” NCT01457911 ↗ |
| Known as | Amaryl - glimepiride | “Amaryl - glimepiride” NCT00576784 ↗1“Amaryl (glimepiride)” NCT01340768 ↗ |
| Known as | glim | “twice-daily biphasic insulin aspart 30 (30% soluble and 70% protaminated insulin aspart; BIAsp 30) plus metformin (met) was compared with once-daily insulin glargine (glarg)...” PMID 17115351 ↗ Oct 20061“glimepiride (GLIM)” PMID 32052516 ↗ Mar 2020 |
| Known as | Glimepirida | ChEMBL registry synonym — accepted as the source's own label CHEMBL1481 ↗ |
| Known as | glimepiride (Amaryl) | “glimepiride (Amaryl)” NCT00000620 ↗1“glimepiride(amaryl)” NCT00474838 ↗ |
| Known as | Glimepiride component of avandaryl | ChEMBL registry synonym — accepted as the source's own label CHEMBL1481 ↗ |
| Known as | Glimepiride component of duetact | ChEMBL registry synonym — accepted as the source's own label CHEMBL1481 ↗ |
| Known as | glimepiride/metformin fixed combination | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00913367 ↗ |
| Known as | Glimerepiride | “Glimerepiride” NCT04239586 ↗ |
| Known as | glimpiride | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02372955 ↗ |
| Known as | HOE 490 | “Determination of the absolute bioavailability of glimepiride (HOE 490), a new
sulphonylurea.” PMID 1490793 ↗ Nov 19923“Drug: Glimepiride (HOE490)” NCT00924573 ↗ “GLIMEPIRIDE (HOE490)” NCT00957060 ↗ “Glimepiride (HOE490)” NCT01457911 ↗ |
| Known as | Niddaryl | ChEMBL registry synonym — accepted as the source's own label CHEMBL1481 ↗ |
| Known as | NSC-759809 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1481 ↗ |
| Known as | Sulfonylurea | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01972724 ↗ |
| Action | Inhibit | “The cardiovascular protective effect of glimepiride may be related to the EET level increase through sEH inhibition.” PMID 36573717 ↗ Dec 2022 |
| Modality | Small molecule | “Glimepiride and glyburide are both second-generation sulfonlyurea drugs used commonly for treatment of type 2 diabetes.” NCT00608179 ↗ |
| Route | Oral | “Pioglitazone placebo-matching tablets, orally, once daily and glimepiride 1 mg titrated up to 4 mg, capsules, orally, once daily” NCT00225264 ↗ |